Methods for modulating the efficacy of nucleic acid based therapies
US7960364B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 11, 2009 |
| Grant date | Jun 14, 2011 |
| Priority date | — |
| Expiry date | Dec 11, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as well as in certain lymphoproliferative disorders. Also provided are methods for modulating the efficacy of nucleic acid based therapeutics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.